All of them tolerated highly selective TACE Saracatinib well, as the residual volume of the normal liver was maintained at least more than 40% the total volume of the liver in each case. In this study 11 patients underwent one-session TACE, and one patient received a second TACE due to unsatisfactory shrinkage of the tumor. Plain CT was performed to evaluate the lipiodol deposition of the lesions in all patients 7-10 days after
each TACE. Conventional serum chemical tests including liver biochemical tests, complete blood cell counts, prothrombin time, and AFP were detected before ablation. In addition, chest radiography, abdominal ultrasonography, and electrocardiogram (ECG) were assessed before HIFU ablation. Enhanced CT or MRI was applied to evaluate the information of each tumor including its size, location, number, and enhancement before treatment and periodically after HIFU ablation. The device used for the HIFU procedure was a Model-JC200 HIFU system (Chongqing Haifu (HIFU) Tech, Chongqing, China). It consisted of US therapy transducers with a US generator, a real-time diagnostic US device, a six-direction
movement system, computer units for automated control, a treatment bed, and a degassed BVD-523 water circulation unit. A 12-cm diameter PZT-4 piezo-ceramic transducer was employed to produce therapeutic US energy. The frequency of the transducers was 0.8 MHz, with various focal lengths ranging from 135 to 155 mm. A US imaging device (Esaote DU3, Genova, Italy) was used as a real-time imaging guidance in the HIFU system, with a 2.5-3.5 MHz probe. This diagnostic probe was situated in the center of the HIFU transducer, and the integrated transducer was then placed in the bag filled with degassed water. HIFU procedure was performed 2-3 weeks after TACE. All patients received general anesthesia for HIFU treatment,
which prevented patient discomfort and mobilization. After suitable anesthesia was achieved, the patient was positioned either prone or on his or her right side, so that the fantofarone skin overlaying the targeted lesion would be easily put in contact with the degassed water. With movement of the integrated transducer, the targeted liver tumor was clearly identified on US imaging, and the targeted volume was divided into parallel slices of 5-mm separation. The operator outlined the margin of the treated region in each of the slices, including the tumor and at least 1 cm of normal tissue surrounding the tumor. The range of the target of the each slice was automatically recorded by the computer in three orthogonal directions. After a detailed planning session was finished, a linear scanning track of HIFU exposure was selected as an ablative scheme. Using provisional therapeutic parameters based on the depth and vascular supply of the target region, the tumor on each slice was completely ablated from the deep to shallow regions, and this process was repeated slice by slice to achieve entire tumor treatment.